In spite of all these promising results, the BEAUTIFUL (morbidity-mortality evaluation of the I f inhibitor ivabradine in patients with coronary disease and left-ventricULar dysfunction) heart failure patient trial concluded that there was no significant reduction in cardiac outcomes with ivabradine in patients with stable coronary artery disease and left ventricular dysfunction [15]. This evidence concerns the gene CFI and heart failure.